Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders

The SIRPα–CD47 immune checkpoint in NK cells

(2021) Tobias Deuse et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Alterations of NK Cell Phenotype in the Disease Course of Multiple Myeloma

(2021) Tatiana Pazina et al.   Cancers

IL-12 Family Cytokines in Cancer and Immunotherapy

(2021) Bhalchandra Mirlekar et al.   Cancers

ADCC against MICA/B Is Mediated against Differentiated Oral and Pancreatic and Not Stem-Like/Poorly Differentiated Tumors by the NK Cells; Loss in Cancer Patients due to Down-Modulation of CD16 Receptor

(2021) Kawaljit Kaur et al.   Cancers

Expansions of adaptive-like NK cells with a tissue-resident phenotype in human lung and blood

(2021) Demi Brownlie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

(2021) Karthik Dhatchinamoorthy et al.   Frontiers in Immunology

Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation

(2021) Zachary Davis et al.   Blood Advances

Metabolic flexibility determines human NK cell functional fate in the tumor microenvironment

(2021) Sophie M. Poznanski et al.   Cell Metabolism

Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies

(2021) Lucila N Kerbauy et al.   CLINICAL CANCER RESEARCH

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

(2021) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial

(2021) Rachel Galot et al.   EUROPEAN JOURNAL OF CANCER

Tissue Determinants of Human NK Cell Development, Function, and Residence

(2020) Pranay Dogra et al.   CELL

Regenerative lineages and immune-mediated pruning in lung cancer metastasis

(2020) Ashley M. Laughney et al.   NATURE MEDICINE

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

(2020) Enli Liu et al.   NEW ENGLAND JOURNAL OF MEDICINE

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells

(2020) Nicola Mitwasi et al.   Scientific Reports

Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?

(2020) Pilar M. Lanuza et al.   Frontiers in Immunology

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer

(2020) Cinzia Fionda et al.   Journal of Clinical Medicine

Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies

(2020) Hui Yi Chew et al.   CELL

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

(2020) Alain P. Algazi et al.   CLINICAL CANCER RESEARCH

The NKG2A - HLA-E axis as a novel checkpoint in the tumor microenvironment

(2020) Linda Borst et al.   CLINICAL CANCER RESEARCH

Single-Cell RNA Sequencing of Tumor-Infiltrating NK Cells Reveals that Inhibition of Transcription Factor HIF-1α Unleashes NK Cell Activity

(2020) Jing Ni et al.   IMMUNITY

Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs

(2020) Alicia M Chenoweth et al.   IMMUNOLOGY AND CELL BIOLOGY

Minimal PD-1 expression in mouse and human NK cells under diverse conditions

(2020) Sean J. Judge et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways

(2020) Teru Hideshima et al.   LEUKEMIA

T cell-engaging therapies — BiTEs and beyond

(2020) Maria-Elisabeth Goebeler et al.   Nature Reviews Clinical Oncology

Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy

(2020) Yuanlin Wu et al.   PHARMACOLOGICAL RESEARCH

ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy

(2020) Jared E Lopes et al.   Journal for ImmunoTherapy of Cancer

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10

(2020) Cristina Bergamaschi et al.   Journal for ImmunoTherapy of Cancer

NK cells mediate clearance of CD8+ T cell–resistant tumors in response to STING agonists

(2020) Christopher J. Nicolai et al.   Science Immunology

Human PCNA Structure, Function and Interactions

(2020) Amaia González-Magaña et al.   Biomolecules

CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity

(2020) Meisam Naeimi Kararoudi et al.   BLOOD

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity

(2020) Huang Zhu et al.   Cell Stem Cell

IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in Melanoma

(2020) Joe-Marc Chauvin et al.   CLINICAL CANCER RESEARCH

IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy

(2020) Ting Zhou et al.   NATURE

The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies

(2020) Tobias Bald et al.   NATURE IMMUNOLOGY

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy

(2020) Kin Man Au et al.   Science Advances

Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer

(2020) Kohei Yamashita et al.   BRITISH JOURNAL OF CANCER

Thioredoxin activity confers resistance against oxidative stress in tumor-infiltrating NK cells

(2020) Ying Yang et al.   JOURNAL OF CLINICAL INVESTIGATION

A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells

(2020) Upasana Sunil Arvindam et al.   LEUKEMIA

Exploring the NK cell platform for cancer immunotherapy

(2020) Jacob A. Myers et al.   Nature Reviews Clinical Oncology

Binding mechanisms of therapeutic antibodies to human CD20

(2020) Anand Kumar et al.   SCIENCE

The Oncometabolite 5′-Deoxy-5′-Methylthioadenosine Blocks Multiple Signaling Pathways of NK Cell Activation

(2020) Benedikt Jacobs et al.   Frontiers in Immunology

Localized Interleukin-12 for Cancer Immunotherapy

(2020) Khue G. Nguyen et al.   Frontiers in Immunology

Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions

(2020) Jules Russick et al.   Journal for ImmunoTherapy of Cancer

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

(2020) Hilma J. van der Horst et al.   Cancers

Antagonistic Inflammatory Phenotypes Dictate Tumor Fate and Response to Immune Checkpoint Blockade

(2020) Eduardo Bonavita et al.   IMMUNITY

Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure compared to recombinant IL-12

(2020) Nuruddeen D. Lewis et al.   MOLECULAR CANCER THERAPEUTICS

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2020) Rupal S. Bhatt et al.   Cancer Immunology Research

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

(2019) Chu-Yu Jing et al.   Journal for ImmunoTherapy of Cancer

Spatial and Temporal Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity

(2019) Naomi A. Yudanin et al.   IMMUNITY

TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer

(2019) Davide Melisi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

The role of cytokines in the regulation of NK cells in the tumor environment

(2019) Gordana M. Konjević et al.   CYTOKINE

Immunophenotypic, cytotoxic, proteomic and genomic characterization of human cord blood vs. peripheral blood CD56Dim NK cells

(2019) Evan Shereck et al.   Innate Immunity

Novel Transforming Growth Factor Beta Receptor I Kinase Inhibitor Galunisertib ( LY 2157299) in Advanced Hepatocellular Carcinoma

(2019) Sandrine Faivre et al.   LIVER INTERNATIONAL

The IRE1 endoplasmic reticulum stress sensor activates natural killer cell immunity in part by regulating c-Myc

(2019) Han Dong et al.   NATURE IMMUNOLOGY

Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity

(2019) Laurent Gauthier et al.   CELL

Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK cell effector function in patients with mantle cell lymphoma

(2019) Thijs W.H. Flinsenberg et al.   HAEMATOLOGICA

Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity

(2019) Kristina Ellwanger et al.   mAbs

Molecular mechanisms of cereblon-based drugs

(2019) Tomoko Asatsuma-Okumura et al.   PHARMACOLOGY & THERAPEUTICS

Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment

(2019) Rachael M. Zemek et al.   Science Translational Medicine

The mechanism of anti-PD-L1 antibody efficacy against PD-L1 negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector

(2019) Wenjuan Dong et al.   Cancer Discovery

Anti–CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control

(2019) Emilio Sanseviero et al.   Cancer Immunology Research

Inhibition of the NKp44-PCNA Immune Checkpoint Using a mAb to PCNA

(2019) Kiran Kundu et al.   Cancer Immunology Research

Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21

(2019) SoonHo Kweon et al.   Frontiers in Immunology

Prognostic Significance of Potential Immune Checkpoint Member HHLA2 in Human Tumors: A Comprehensive Analysis

(2019) Ben Wang et al.   Frontiers in Immunology

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival

(2019) Andrea Gras Navarro et al.   Cancers

Ublituximab and Umbralisib in Relapsed/ Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

(2019) Matthew Lunning et al.   BLOOD

Chronic stimulation drives human NK cell dysfunction and epigenetic reprograming

(2019) Aimee Merino et al.   JOURNAL OF CLINICAL INVESTIGATION

Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma

(2019) Tatiana Pazina et al.   Cancer Immunology Research

MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner

(2019) Changchun Du et al.   Journal for ImmunoTherapy of Cancer

Functional Attributes of Antibodies, Effector Cells, and Target Cells Affecting NK Cell–Mediated Antibody-Dependent Cellular Cytotoxicity

(2019) A. Robin Temming et al.   JOURNAL OF IMMUNOLOGY

Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance

(2019) Xiaohu Zheng et al.   NATURE IMMUNOLOGY

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2019) Kelsey E. Sivick et al.   Cell Reports

Post-translational Mechanisms Regulating NK Cell Activating Receptors and Their Ligands in Cancer: Potential Targets for Therapeutic Intervention

(2019) Rosa Molfetta et al.   Frontiers in Immunology

Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells

(2019) Valentina Bonanni et al.   Journal for ImmunoTherapy of Cancer

A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment

(2019) Huynh et al.   Biomolecules

Pluripotent stem cell–derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity

(2019) Huang Zhu et al.   BLOOD

Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells

(2019) L. Herrera et al.   Scientific Reports

NK Cell Metabolism and TGFβ – Implications for Immunotherapy

(2019) Karen Slattery et al.   Frontiers in Immunology

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

(2018) Rizwan Romee et al.   BLOOD

CD271+ cells are diagnostic and prognostic and exhibit elevated MAPK activity in SHH medulloblastoma

(2018) Lisa Liang et al.   CANCER RESEARCH

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity

(2018) Ye Li et al.   Cell Stem Cell

Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer

(2018) Silvia C. Formenti et al.   CLINICAL CANCER RESEARCH

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1–Negative Human Lung Cancers

(2018) Haiying Cheng et al.   CLINICAL CANCER RESEARCH

CTLA-4 regulates human Natural Killer cell effector functions

(2018) Vassilios Lougaris et al.   CLINICAL IMMUNOLOGY

Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells

(2018) Katja Srpan et al.   JOURNAL OF CELL BIOLOGY

A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma

(2018) Michael J. Robertson et al.   JOURNAL OF IMMUNOTHERAPY

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

(2018) John M Wrangle et al.   LANCET ONCOLOGY

Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity

(2018) Qing Zhang et al.   NATURE IMMUNOLOGY

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell–driven tumor immunity

(2018) Lucas Ferrari de Andrade et al.   SCIENCE

SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy

(2018) André Veillette et al.   TRENDS IN IMMUNOLOGY

Intrinsic Functional Potential of NK-Cell Subsets Constrains Retargeting Driven by Chimeric Antigen Receptors

(2018) Vincent Yi Sheng Oei et al.   Cancer Immunology Research

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors

(2018) Brian J. Francica et al.   Cancer Immunology Research

Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing γδ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells

(2018) Hans H. Oberg et al.   Frontiers in Immunology

Natural killer cells in inflammation and autoimmunity

(2018) Beatrice Zitti et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells

(2018) Linda Quatrini et al.   NATURE IMMUNOLOGY

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

(2018) Estefanía Paula Juliá et al.   Frontiers in Immunology

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines

(2018) Nadine van Montfoort et al.   CELL

Gene Regulatory Programs Conferring Phenotypic Identities to Human NK Cells

(2018) Patrick L. Collins et al.   CELL

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

(2018) Assaf Marcus et al.   IMMUNITY

High-Dimensional Single-Cell Analysis Identifies Organ-Specific Signatures and Conserved NK Cell Subsets in Humans and Mice

(2018) Adeline Crinier et al.   IMMUNITY

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

(2018) Meletios A. Dimopoulos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis

(2018) Cathal Harmon et al.   Cancer Immunology Research

Adenosinergic Signaling Alters Natural Killer Cell Functional Responses

(2018) Andrea M. Chambers et al.   Frontiers in Immunology

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

(2018) Kerry S. Campbell et al.   Frontiers in Immunology

PD-1 in human NK cells: evidence of cytoplasmic mRNA and protein expression

(2018) Francesca R. Mariotti et al.   OncoImmunology

The Broad Spectrum of Human Natural Killer Cell Diversity

(2017) Aharon G. Freud et al.   IMMUNITY

Interleukin-18: Biological properties and role in disease pathogenesis

(2017) Gilles Kaplanski   IMMUNOLOGICAL REVIEWS

Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization

(2017) Silvia Pesce et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Contribution of inhibitory receptor TIGIT to NK cell education

(2017) Yuke He et al.   JOURNAL OF AUTOIMMUNITY

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

(2017) Umberto Vitolo et al.   JOURNAL OF CLINICAL ONCOLOGY

IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity

(2017) Martina Molgora et al.   NATURE

Obinutuzumab for the First-Line Treatment of Follicular Lymphoma

(2017) Robert Marcus et al.   NEW ENGLAND JOURNAL OF MEDICINE

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy

(2017) Zachary B. Davis et al.   SEMINARS IN IMMUNOLOGY

A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy

(2017) Brent A. Williams et al.   Oncotarget

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity

(2017) Jörg U. Schmohl et al.   Cancer Research and Treatment

Regulation of the Functions of Natural Cytotoxicity Receptors by Interactions with Diverse Ligands and Alterations in Splice Variant Expression

(2017) Tatiana Pazina et al.   Frontiers in Immunology

NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors

(2017) Alexander W. MacFarlane et al.   OncoImmunology

The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and –independent mechanisms

(2017) Tatiana Pazina et al.   OncoImmunology

PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO

(2017) Nikolai Siebert et al.   OncoImmunology

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients

(2017) Rossana Tallerico et al.   OncoImmunology

TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells

(2016) Hung C. Tran et al.   CLINICAL CANCER RESEARCH

Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

(2016) Z. Ma et al.   CLINICAL CANCER RESEARCH

CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer

(2016) Raghvendra M. Srivastava et al.   CLINICAL CANCER RESEARCH

Checkpoint Inhibition of KIR2D with the Monoclonal Antibody IPH2101 Induces Contraction and Hyporesponsiveness of NK Cells in Patients with Myeloma

(2016) M. Carlsten et al.   CLINICAL CANCER RESEARCH

Cell-Extrinsic MHC Class I Molecule Engagement Augments Human NK Cell Education Programmed by Cell-Intrinsic MHC Class I

(2016) Jeanette E. Boudreau et al.   IMMUNITY

Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes

(2016) M. A. Hauser et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Interleukin 21 – its potential role in the therapy of B-cell lymphomas

(2016) Shruti Bhatt et al.   LEUKEMIA & LYMPHOMA

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

(2016) Qi Chen et al.   NATURE IMMUNOLOGY

Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia

(2016) Rizwan Romee et al.   Science Translational Medicine

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma

(2016) Chao Niu et al.   Oncotarget

An NK cell line (haNK) expressing high levels of granzyme and engineered to express the high affinity CD16 allele

(2016) Caroline Jochems et al.   Oncotarget

IL-15 superagonist/IL-15RαSushi-Fc fusion complex (IL-15SA/IL-15RαSu-Fc; ALT-803) markedly enhances specific subpopulations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas

(2016) Peter S. Kim et al.   Oncotarget

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation

(2016) G. C. Sim et al.   Cancer Immunology Research

Efficient mRNA-Based Genetic Engineering of Human NK Cells with High-Affinity CD16 and CCR7 Augments Rituximab-Induced ADCC against Lymphoma and Targets NK Cell Migration toward the Lymph Node-Associated Chemokine CCL19

(2016) Mattias Carlsten et al.   Frontiers in Immunology

Human Circulating and Tissue-Resident CD56bright Natural Killer Cell Populations

(2016) Janine E. Melsen et al.   Frontiers in Immunology

Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds

(2015) K. Lagrue et al.   BLOOD

Interleukin-12: Functional activities and implications for disease

(2015) Sebastian Zundler et al.   CYTOKINE & GROWTH FACTOR REVIEWS

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity

(2015) Olivier Demaria et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer

(2015) David L. Hermanson et al.   STEM CELLS

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma

(2015) Cinzia Fionda et al.   Oncotarget

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Identification of an ADAM17 Cleavage Region in Human CD16 (FcγRIII) and the Engineering of a Non-Cleavable Version of the Receptor in NK Cells

(2015) Yawu Jing et al.   PLoS One

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

(2014) M. Janakiram et al.   CLINICAL CANCER RESEARCH

Blocking NK Cell Inhibitory Self-Recognition Promotes Antibody-Dependent Cellular Cytotoxicity in a Model of Anti-Lymphoma Therapy

(2014) Liat Binyamin et al.   JOURNAL OF IMMUNOLOGY

CD56brightPerforinlow Noncytotoxic Human NK Cells Are Abundant in Both Healthy and Neoplastic Solid Tissues and Recirculate to Secondary Lymphoid Organs via Afferent Lymph

(2014) P. Carrega et al.   JOURNAL OF IMMUNOLOGY

Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

(2014) Marina Fabbi et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma

(2014) John C. Morris et al.   PLoS One

Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade

(2014) I. P. da Silva et al.   Cancer Immunology Research

NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17)

(2013) R. Romee et al.   BLOOD

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15: Interleukin-15 Receptor  Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma

(2013) W. Xu et al.   CANCER RESEARCH

Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC

(2013) Mirna Balsamo et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Natural killer cell deficiency

(2013) Jordan S. Orange   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Natural killer cell biology: An update and future directions

(2013) Kerry S. Campbell et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A Dose-Escalation Study of Recombinant Human Interleukin-18 in Combination With Rituximab in Patients With Non-Hodgkin Lymphoma

(2013) Michael J. Robertson et al.   JOURNAL OF IMMUNOTHERAPY

Fratricide of natural killer cells dressed with tumor-derived NKG2D ligand

(2013) Kyohei Nakamura et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

Genetic and Environmental Determinants of Human NK Cell Diversity Revealed by Mass Cytometry

(2013) A. Horowitz et al.   Science Translational Medicine

Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy

(2013) David A. Knorr et al.   Stem Cells Translational Medicine

Circulating IL-15 exists as heterodimeric complex with soluble IL-15R  in human and mouse serum

(2012) C. Bergamaschi et al.   BLOOD

The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells

(2012) P Glorius et al.   LEUKEMIA

HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1

(2012) Jeffrey M. Venstrom et al.   NEW ENGLAND JOURNAL OF MEDICINE

The application and biology of immunomodulatory drugs (IMiDs) in cancer

(2012) Beiqing Pan et al.   PHARMACOLOGY & THERAPEUTICS

Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism

(2011) S. Veeramani et al.   BLOOD

Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function

(2011) B. Foley et al.   BLOOD

IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization

(2011) Kai-ping Han et al.   CYTOKINE

Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations

(2011) Kerry S. Campbell et al.   IMMUNOLOGY

Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity

(2011) Emilie Mamessier et al.   JOURNAL OF CLINICAL INVESTIGATION

Proliferating Cell Nuclear Antigen Is a Novel Inhibitory Ligand for the Natural Cytotoxicity Receptor NKp44

(2011) B. Rosental et al.   JOURNAL OF IMMUNOLOGY

Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection

(2011) S. Lopez-Verges et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition

(2010) K. Schonberg et al.   BLOOD

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

(2010) S. Cooley et al.   BLOOD

Natural killer cells and cancer: Regulation by the killer cell Ig-like receptors (KIR)

(2010) Amanda K. Purdy et al.   CANCER BIOLOGY & THERAPY

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

(2010) M Q Lacy et al.   LEUKEMIA

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

Functionally distinct subsets of human NK cells and monocyte/DC-like cells identified by coexpression of CD56, CD7, and CD4

(2009) J. M. Milush et al.   BLOOD

Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells

(2009) F. Romagne et al.   BLOOD

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

STING regulates intracellular DNA-mediated, type I interferon-dependent innate immunity

(2009) Hiroki Ishikawa et al.   NATURE

Enhanced NK-cell development and function in BCAP-deficient mice

(2008) A. W. MacFarlane et al.   BLOOD

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Senescence of Activated Stellate Cells Limits Liver Fibrosis

(2008) Valery Krizhanovsky et al.   CELL

A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer

(2008) M. J. Robertson et al.   CLINICAL CANCER RESEARCH

Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma

(2008) S. Armeanu et al.   CLINICAL CANCER RESEARCH

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA alleles determine differences in human natural killer cell responsiveness and potency

(2008) S. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

(2008) M. Jinushi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Yin and Yang of HLA and KIR in human disease

(2008) Smita Kulkarni et al.   SEMINARS IN IMMUNOLOGY

Interleukin-21 activates human natural killer cells and modulates their surface receptor expression

(2007) Kresten Skak et al.   IMMUNOLOGY